BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191021
DTEND;VALUE=DATE:20191023
DTSTAMP:20260515T022820
CREATED:20190514T110507Z
LAST-MODIFIED:20190514T110507Z
UID:20716-1571616000-1571788799@www.pharmajournalist.com
SUMMARY:Highly Potent Active Pharmaceutical Ingredients USA (HPAPI) Conference
DESCRIPTION:SMi is delighted to announce its USA Highly Potent Active Pharmaceutical Ingredients conference coming to Boston on the 21th – 22th October 2019. \nThe inaugural HPAPI USA conference will explore how current technologies are streamlining the HPAPI industry with artificial intelligence and machine learning\, to improve risk assessment and validation. The latest emerging therapies will be discussed including bispecific antibodies\, oncolytic viral complexes and hormones. Will the super-high level 5 banding for these biologics prove effective or inept? Are current containment planning and solutions truly ensuing the health of workers? These questions will be answered along with unique insights including HPAPI manufacturing technologies. \nAttend the conference and join our networking platform with industry professionals to provide you with the expertise to overcome challenges. \nDISCUSSION HIGHLIGHTS: \nOncology Antibody-Drug Conjugates (ADC)\, the ongoing developments and the containment challenges imposed \nHow to correctly assess\, plan and implement the most cost-effective containment \nEmerging HPAPI therapies\, oncolytic viruses their potential and challenges \nAlternative HPAPI manufacturing technologies to reduce powder exposure and improving safety along with enabling continuous manufacturing \nThe reality of oncology ADC and HPAPI: are most drugs using ‘highly-potent’ to improve brand image? Has 50 years of ADC R&D for oncology with no cure shows signs of no promise? \nView the full agenda: www.hpapi-usa.com/PJwl
URL:https://www.pharmajournalist.com/event/highly-potent-active-pharmaceutical-ingredients-usa-hpapi-conference/
LOCATION:Sheraton Boston Hotel\, Boston USA\, United States
ORGANIZER;CN="SMi Group Limited":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
END:VCALENDAR